Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that leads to a decline in platelet production, thus increasing the risk of bleeding. Current therapies for ITP can be broadly…
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the Asia-Pacific (Australia, Hong Kong, Taiwan,…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the Middle East and Africa (Egypt, Nigeria, Saudi Arabia…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia,…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China,…
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark,…
Immunoglobulin A nephropathy (IgAN or IgA nephropathy), also known as Berger’s disease, is a rare autoimmune condition that damages the glomeruli inside the kidneys. Initial treatment of IgAN…
Acute coronary syndrome (ACS)—subtype of coronary artery disease (CAD)—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
The hepatocellular carcinoma therapy market is gradually evolving and experiencing substantial growth. While angiogenesis inhibitors, including sorafenib (Bayer / Amgen), Stivarga (Bayer), Lenvima…
Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. For 13 years, AbbVie’s Restasis was…
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…